Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

RBOT vs MASI

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
RBOT
Vicarious Surgical Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$3M
5Y Perf.-99.8%
MASI
Masimo Corporation

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$9.35B
5Y Perf.-24.4%

RBOT vs MASI — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
RBOT logoRBOT
MASI logoMASI
IndustryMedical - DevicesMedical - Instruments & Supplies
Market Cap$3M$9.35B
Revenue (TTM)$0.00$1.56B
Net Income (TTM)$-42M$76M
Gross Margin61.7%
Operating Margin19.9%
Forward P/E32.5x
Total Debt$8M$559M
Cash & Equiv.$3M$152M

RBOT vs MASILong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

RBOT
MASI
StockSep 20May 26Return
Vicarious Surgical … (RBOT)1000.2-99.8%
Masimo Corporation (MASI)10075.6-24.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: RBOT vs MASI

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MASI leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Vicarious Surgical Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
RBOT
Vicarious Surgical Inc.
The Growth Leader

RBOT is the clearest fit if your priority is growth and quality.

  • 31.5% revenue growth vs MASI's -27.1%
  • 5.0% margin vs MASI's 4.9%
Best for: growth and quality
MASI
Masimo Corporation
The Income Pick

MASI carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 0 yrs, beta 0.63
  • Rev growth -27.1%, EPS growth 51.0%, 3Y rev CAGR -9.1%
  • 282.9% 10Y total return vs RBOT's -99.8%
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthRBOT logoRBOT31.5% revenue growth vs MASI's -27.1%
Quality / MarginsRBOT logoRBOT5.0% margin vs MASI's 4.9%
Stability / SafetyMASI logoMASIBeta 0.63 vs RBOT's 1.92, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)MASI logoMASI+18.9% vs RBOT's -94.1%
Efficiency (ROA)MASI logoMASI4.0% ROA vs RBOT's -164.5%, ROIC 16.5% vs -116.2%

RBOT vs MASI — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

RBOTVicarious Surgical Inc.

Segment breakdown not available.

MASIMasimo Corporation
FY 2025
Health Care Segment
100.0%$1.5B

RBOT vs MASI — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMASILAGGINGRBOT

Income & Cash Flow (Last 12 Months)

MASI leads this category, winning 1 of 1 comparable metric.

MASI and RBOT operate at a comparable scale, with $1.6B and $0 in trailing revenue.

MetricRBOT logoRBOTVicarious Surgica…MASI logoMASIMasimo Corporation
RevenueTrailing 12 months$0$1.6B
EBITDAEarnings before interest/tax-$42M$340M
Net IncomeAfter-tax profit-$42M$76M
Free Cash FlowCash after capex-$40M$211M
Gross MarginGross profit ÷ Revenue+61.7%
Operating MarginEBIT ÷ Revenue+19.9%
Net MarginNet income ÷ Revenue+4.9%
FCF MarginFCF ÷ Revenue+13.6%
Rev. Growth (YoY)Latest quarter vs prior year+8.5%
EPS Growth (YoY)Latest quarter vs prior year+58.1%+134.4%
MASI leads this category, winning 1 of 1 comparable metric.

Valuation Metrics

Evenly matched — RBOT and MASI each lead in 1 of 2 comparable metrics.
MetricRBOT logoRBOTVicarious Surgica…MASI logoMASIMasimo Corporation
Market CapShares × price$3M$9.3B
Enterprise ValueMkt cap + debt − cash$8M$9.8B
Trailing P/EPrice ÷ TTM EPS-0.06x-63.75x
Forward P/EPrice ÷ next-FY EPS est.32.46x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple27.74x
Price / SalesMarket cap ÷ Revenue6.12x
Price / BookPrice ÷ Book value/share0.30x13.41x
Price / FCFMarket cap ÷ FCF47.26x
Evenly matched — RBOT and MASI each lead in 1 of 2 comparable metrics.

Profitability & Efficiency

MASI leads this category, winning 6 of 8 comparable metrics.

MASI delivers a 9.1% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-3 for RBOT. MASI carries lower financial leverage with a 0.78x debt-to-equity ratio, signaling a more conservative balance sheet compared to RBOT's 0.79x. On the Piotroski fundamental quality scale (0–9), MASI scores 6/9 vs RBOT's 1/9, reflecting solid financial health.

MetricRBOT logoRBOTVicarious Surgica…MASI logoMASIMasimo Corporation
ROE (TTM)Return on equity-3.3%+9.1%
ROA (TTM)Return on assets-164.5%+4.0%
ROICReturn on invested capital-116.2%+16.5%
ROCEReturn on capital employed-134.6%+18.8%
Piotroski ScoreFundamental quality 0–916
Debt / EquityFinancial leverage0.79x0.78x
Net DebtTotal debt minus cash$5M$407M
Cash & Equiv.Liquid assets$3M$152M
Total DebtShort + long-term debt$8M$559M
Interest CoverageEBIT ÷ Interest expense12.50x
MASI leads this category, winning 6 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

MASI leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in MASI five years ago would be worth $7,963 today (with dividends reinvested), compared to $16 for RBOT. Over the past 12 months, MASI leads with a +18.9% total return vs RBOT's -94.1%. The 3-year compound annual growth rate (CAGR) favors MASI at -1.7% vs RBOT's -80.2% — a key indicator of consistent wealth creation.

MetricRBOT logoRBOTVicarious Surgica…MASI logoMASIMasimo Corporation
YTD ReturnYear-to-date-80.6%+40.1%
1-Year ReturnPast 12 months-94.1%+18.9%
3-Year ReturnCumulative with dividends-99.2%-4.9%
5-Year ReturnCumulative with dividends-99.8%-20.4%
10-Year ReturnCumulative with dividends-99.8%+282.9%
CAGR (3Y)Annualised 3-year return-80.2%-1.7%
MASI leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

MASI leads this category, winning 2 of 2 comparable metrics.

MASI is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than RBOT's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MASI currently trades 99.7% from its 52-week high vs RBOT's 3.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricRBOT logoRBOTVicarious Surgica…MASI logoMASIMasimo Corporation
Beta (5Y)Sensitivity to S&P 5001.92x0.63x
52-Week HighHighest price in past year$13.75$179.10
52-Week LowLowest price in past year$0.35$125.94
% of 52W HighCurrent price vs 52-week peak+3.6%+99.7%
RSI (14)Momentum oscillator 0–10030.063.8
Avg Volume (50D)Average daily shares traded24K1.2M
MASI leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricRBOT logoRBOTVicarious Surgica…MASI logoMASIMasimo Corporation
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$187.50
# AnalystsCovering analysts23
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+3.9%
Insufficient data to determine a leader in this category.
Key Takeaway

MASI leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.

Best OverallMasimo Corporation (MASI)Leads 4 of 6 categories
Loading custom metrics...

RBOT vs MASI: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is RBOT or MASI a better buy right now?

Analysts rate Masimo Corporation (MASI) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison.

The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — RBOT or MASI?

Over the past 5 years, Masimo Corporation (MASI) delivered a total return of -20.

4%, compared to -99. 8% for Vicarious Surgical Inc. (RBOT). Over 10 years, the gap is even starker: MASI returned +282. 9% versus RBOT's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — RBOT or MASI?

By beta (market sensitivity over 5 years), Masimo Corporation (MASI) is the lower-risk stock at 0.

63β versus Vicarious Surgical Inc. 's 1. 92β — meaning RBOT is approximately 206% more volatile than MASI relative to the S&P 500. On balance sheet safety, Masimo Corporation (MASI) carries a lower debt/equity ratio of 78% versus 79% for Vicarious Surgical Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — RBOT or MASI?

On earnings-per-share growth, the picture is similar: Masimo Corporation grew EPS 51.

0% year-over-year, compared to 21. 2% for Vicarious Surgical Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — RBOT or MASI?

Vicarious Surgical Inc.

(RBOT) is the more profitable company, earning 0. 0% net margin versus -9. 9% for Masimo Corporation — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MASI leads at 20. 5% versus 0. 0% for RBOT. At the gross margin level — before operating expenses — MASI leads at 61. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — RBOT or MASI?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is RBOT or MASI better for a retirement portfolio?

For long-horizon retirement investors, Masimo Corporation (MASI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

63), +282. 9% 10Y return). Vicarious Surgical Inc. (RBOT) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MASI: +282. 9%, RBOT: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between RBOT and MASI?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

RBOT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

MASI

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 37%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.